IGF-1 drug approved by FDA

by Medindia Content Team on  November 26, 2005 at 6:37 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

IGF-1 drug approved by FDA
Insulin like-Growth Factor (IGF-1) is required for both cartilage and bone growth in children's and the secretion of IGF is mediated by the pituitary gland. Deficiency of IGF-1 results in impaired growth and is associated with metabolic abnormalities including insulin resistance, increased adiposity and delayed wound healing. IGF-1 drugs helps in production of IGF-1 in children's with deficiency in production of IGF-1.

The pharmaceutical company Tercica drug, Increlex against IGF-1 deficiency has been approved by the U.S. FDA to produce recombinant human IGF-1 as a long term treatment for children with severe primary IGF-1 deficiency. The results of the new recombinant drug has to be monitored as earlier IGF-1 drugs produced by pharmaceuticals like Genetech for treatment of diabetes and Cephalon pharmacies IGF-1 drug against Amyotrophic lateral sclerosis had been withdrawn due to its side effects in patients.


Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive